Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease

Authors

  • Rodger J. Elble MD, PhD,

    Corresponding author
    1. Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    • Department of Neurology, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL
    Search for more papers by this author
  • Oksana Suchowersky MD,

    1. Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada
    Search for more papers by this author
  • Stephanie Shaftman MSc, MS,

    1. Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    2. Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA
    Search for more papers by this author
  • William J. Weiner MD,

    1. Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Search for more papers by this author
  • Peng Huang PhD,

    1. Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Search for more papers by this author
  • Barbara Tilley PhD,

    1. Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA
    Search for more papers by this author
  • On Behalf of the NINDS NET-PD Investigators

    1. Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA
    Search for more papers by this author
    • Members of the “NET-PD Steering Committee” are listed as an Appendix.


  • Potential conflict of interest: Nothing to report.

Abstract

We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q10 and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society

Ancillary